In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO of InMed Pharmaceuticals, the Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Max and Eric discuss Cannabinol (CBN), the minor cannabinoid at the heart of InMed’s programs, why the company chose it and the advantages it may have over cannabiodiol (CBD) and tetrahydrocannabinol (THC).
In the Media
Maxim Jacobs Interviews Eric A. Adams about InMed’s Programs Using Cannabinol CBN
Share this post
Latest Media News
In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to
InMed’s therapeutic development of cannabinol and update on programs – Executive Interview with CEO Eric A. Adams
In this video, InMed Pharmaceuticals’ CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat